Eton Pharmaceuticals, Inc. (NASDAQ:ETON)
| Market Cap | 1.52B+180.7% |
| Revenue (ttm) | 105.59M+81.5% |
| Net Income | 12.69M+407.4% |
| EPS | 0.38+349.9% |
| Shares Out | 27.39M |
| PE Ratio | 119.69 |
| Forward PE | 26.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 379,216 |
| Open | 56.96 |
| Previous Close | 57.09 |
| Day's Range | 54.24 - 56.96 |
| 52-Week Range | 14.27 - 66.37 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 66.67(+19.79%) |
| Earnings Date | Nov 5, 2026 |
Eton Pharmaceuticals, Inc. has a live Insider Score.
Scored on 0 qualifying trades from 0 insiders in the last 90 days.
About ETON
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ETON stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ETON by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Thomas SuozziHouse / D | Purchase$15.00K – $50.00K | Oct 11, 2022 |
Recently reported changes in ETON holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ETON's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ETON Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ETON patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ETON from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ETON
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $42.13M |
| IWMiShares Russell 2000 ETF | $36.73M |
| VXFVanguard Extended Market ETF | $16.55M |
| IWOiShares Russell 2000 Growth ETF | $13.78M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $10.17M |
| VTWOVanguard Russell 2000 ETF | $9.28M |
Estimated from each fund’s disclosed top holdings × AUM
ETON Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ETON’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score